The US Chamber of Commerce has urged the Canadian government to address its ‘promise utility doctrine’, claiming that it “dramatically undermines legal certainty for medical innovators in Canada”.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Canada, promise doctrine, patent, NAFTA, ICSID, Eli Lilly, innovation, PhRMA, US Chamber of Commerce